Results 211 to 220 of about 66,883 (257)
Some of the next articles are maybe not open access.

Related searches:

Immune Checkpoint Inhibitors in the Aged

Current Oncology Reports, 2021
Large phase III trials have established the benefit of checkpoint blockade across multiple tumor types, but patient representation is limited in some subgroups including the aged population. There are several changes in the immune system that occur with age (termed immunosenescence) that could potentially limit efficacy in aged populations.Despite the ...
James Isaacs   +2 more
openaire   +2 more sources

Immune Checkpoint Blockade

Hematology/Oncology Clinics of North America, 2014
Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs.
Jarushka, Naidoo   +2 more
openaire   +2 more sources

Immune checkpoint inhibitors and vasculitis

Current Opinion in Rheumatology, 2020
Purpose of review Clinical use of immune checkpoint inhibitor (ICI) therapy has revolutionized the therapeutic landscape of cancer. By activating the immune system using monoclonal anti-CTLA-4 and PD(L)-1 antibodies, remission can be induced in previously terminal cancers. However, these breakthroughs come at a price.
Patrick, Boland   +2 more
openaire   +2 more sources

Immune checkpoint receptors in autoimmunity

Current Opinion in Immunology, 2023
Immune checkpoint receptors such as programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3), and T cell immunoglobulin and ITIM domain (TIGIT) have distinct and overlapping inhibitory functions that regulate Tcell activation, differentiation, and function.
Kelly P, Burke   +3 more
openaire   +2 more sources

Epigenetics Meets Immune Checkpoints

Seminars in Oncology, 2015
Epigenetic alterations play a pivotal role in cancer development and progression. Pharmacologic reversion of such alterations is feasible, and second generation "epigenetic drugs" are in development and have been demonstrated to possess significant immunomodulatory properties.
Covre A.   +5 more
openaire   +3 more sources

Immune checkpoint inhibitors in GBM

Journal of Neuro-Oncology, 2021
The purpose of this review is to summarize recent updates regarding immune checkpoint inhibitor therapy in GBM patients including updates in brain immunology, clinical trials, mechanisms of resistance, and biomarkers of response.PubMed was searched to identify recent relevant articles on immune checkpoint inhibitor therapy as it pertains to GBM ...
openaire   +2 more sources

CD200 is an atheroprotective immune checkpoint

Nature Reviews Cardiology, 2021
The CD200 inhibitory immune checkpoint promotes arterial homeostasis and reduces atherosclerotic plaque progression and inflammation in mice by limiting the excessive supply, recruitment and activation of monocytes and macrophages during atherogenesis, according to a new study.
openaire   +2 more sources

Immune checkpoints in the tumor microenvironment

Seminars in Cancer Biology, 2020
Interactions between immune checkpoints (ICs) and their ligands negatively regulate T cell activation pathways involved in physiological immune responses against specific antigens. ICs and their ligands are frequently upregulated in the tumor microenvironment (TME) of various malignancies, and they represent significant barriers for induction of ...
Salman M Toor   +2 more
exaly   +3 more sources

Home - About - Disclaimer - Privacy